Arrowhead Pharmaceuticals (ARWR) Competitors $30.69 -0.82 (-2.60%) Closing price 04:00 PM EasternExtended Trading$31.20 +0.51 (+1.66%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARWR vs. SMMT, RDY, ASND, VTRS, QGEN, BBIO, ROIV, MRNA, ELAN, and VRNAShould you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Moderna (MRNA), Elanco Animal Health (ELAN), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Arrowhead Pharmaceuticals vs. Its Competitors Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris QIAGEN BridgeBio Pharma Roivant Sciences Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation. Is ARWR or SMMT more profitable? Arrowhead Pharmaceuticals' return on equity of -40.91% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arrowhead PharmaceuticalsN/A -40.91% -11.62% Summit Therapeutics N/A -208.64%-181.28% Which has preferable valuation and earnings, ARWR or SMMT? Summit Therapeutics has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArrowhead Pharmaceuticals$3.55M1,195.27-$599.49M-$1.28-23.98Summit Therapeutics$700K20,046.34-$221.32M-$1.01-18.70 Does the media prefer ARWR or SMMT? In the previous week, Arrowhead Pharmaceuticals had 6 more articles in the media than Summit Therapeutics. MarketBeat recorded 27 mentions for Arrowhead Pharmaceuticals and 21 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.83 beat Arrowhead Pharmaceuticals' score of 0.41 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 6 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 8 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in ARWR or SMMT? 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 84.9% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, ARWR or SMMT? Arrowhead Pharmaceuticals has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Summit Therapeutics has a beta of -1.02, suggesting that its stock price is 202% less volatile than the S&P 500. Do analysts recommend ARWR or SMMT? Arrowhead Pharmaceuticals currently has a consensus price target of $43.14, suggesting a potential upside of 40.58%. Summit Therapeutics has a consensus price target of $31.87, suggesting a potential upside of 68.70%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Arrowhead Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.00Summit Therapeutics 4 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.56 SummaryArrowhead Pharmaceuticals and Summit Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARWR vs. The Competition Export to ExcelMetricArrowhead PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.24B$3.12B$5.75B$10.42BDividend YieldN/A2.37%5.74%4.63%P/E Ratio-23.9820.6576.5526.74Price / Sales1,195.27385.03494.58162.18Price / CashN/A45.3237.1760.63Price / Book19.939.6613.726.40Net Income-$599.49M-$53.02M$3.29B$271.71M7 Day Performance3.26%1.09%1.03%2.85%1 Month Performance54.53%7.93%6.32%9.64%1 Year Performance45.18%10.48%81.16%31.62% Arrowhead Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARWRArrowhead Pharmaceuticals4.2236 of 5 stars$30.69-2.6%$43.14+40.6%+51.6%$4.24B$3.55M-23.98400Insider TradeAnalyst RevisionHigh Trading VolumeSMMTSummit Therapeutics3.2191 of 5 stars$18.94flat$33.79+78.4%-21.7%$14.07BN/A-18.75110Analyst ForecastRDYDr. Reddy's Laboratories2.3701 of 5 stars$14.64-0.2%$16.95+15.8%-6.0%$12.22B$3.81B22.1727,811ASNDAscendis Pharma A/S3.047 of 5 stars$194.62-0.5%$244.36+25.6%+33.9%$11.91B$490.75M-37.721,017Positive NewsVTRSViatris1.361 of 5 stars$9.60-3.6%$10.40+8.3%-17.1%$11.19B$14.74B-3.3132,000QGENQIAGEN4.4439 of 5 stars$45.39+0.2%$49.69+9.5%+3.0%$10.09B$1.98B26.825,765Positive NewsBBIOBridgeBio Pharma4.337 of 5 stars$51.47+0.5%$63.94+24.2%+105.4%$9.84B$221.90M-12.58400ROIVRoivant Sciences3.4738 of 5 stars$13.95-0.9%$17.67+26.6%+25.8%$9.53B$29.05M-19.93860Trending NewsAnalyst ForecastMRNAModerna4.5233 of 5 stars$23.88+1.6%$41.81+75.1%-63.6%$9.29B$3.24B-3.175,800ELANElanco Animal Health2.8364 of 5 stars$18.63+0.5%$17.33-6.9%+30.5%$9.25B$4.44B21.669,000VRNAVerona Pharma PLC American Depositary Share2.1667 of 5 stars$106.37-0.1%$109.00+2.5%+263.5%$9.17B$42.28M-107.4430Positive News Related Companies and Tools Related Companies Summit Therapeutics Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives QIAGEN Alternatives BridgeBio Pharma Alternatives Roivant Sciences Alternatives Moderna Alternatives Elanco Animal Health Alternatives Verona Pharma PLC American Depositary Share Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARWR) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARWR Stock Alerts